S&CO Inc’s AbbVie ABBV Stock Holding History

S&CO Inc’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.27M	Sell	5,857 -235	-4%	-$52.1K	0.08%	131
2025 Q4	$1.39M	Hold	6,092	–	–	0.09%	127
2025 Q3	$1.41M	Hold	6,092	–	–	0.09%	128
2025 Q2	$1.13M	Hold	6,092	–	–	0.07%	141
2025 Q1	$1.28M	Buy	6,092 +4,338	+247%	+$843K	0.09%	133
2024 Q4	$311K	Hold	1,754	–	–	0.02%	182
2024 Q3	$346K	Hold	1,754	–	–	0.02%	186
2024 Q2	$300K	Hold	1,754	–	–	0.02%	192
2024 Q1	$319K	Hold	1,754	–	–	0.02%	181
2023 Q4	$271K	Buy	1,754 +133	+8%	+$19.4K	0.02%	169
2023 Q3	$241K	Buy	+1,621	New	+$238K	0.02%	162
2015 Q2	–	Sell	-199,075	Closed	-$11.7M	–	146
2015 Q1	$11.7M	Buy	199,075 +7,562	+4%	+$457K	1.66%	22
2014 Q4	$12.5M	Buy	191,513 +946	+0.5%	+$59.6K	1.82%	18
2014 Q3	$11M	Sell	190,567 -89,772	-32%	-$4.98M	1.68%	21
2014 Q2	$15.8M	Sell	280,339 -5,907	-2%	-$310K	2.2%	16
2014 Q1	$14.7M	Sell	286,246 -100	-0%	-$5.05K	2.2%	15
2013 Q4	$15.1M	Sell	286,346 -80	-0%	-$3.93K	2.53%	11
2013 Q3	$12.8M	Hold	286,426	–	–	2.25%	14
2013 Q2	$11.8M	Buy	+286,426	New	+$12.5M	1.8%	19

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

S&CO Inc's ABBV Position: Q1 2026 in Review

S&CO Inc reduced its AbbVie (ABBV) stake by 3.9% in Q1 2026, selling an estimated $52.1K and leaving 5,857 shares worth $1.27M. The position accounts for 0.08% of the portfolio, ranked #131.

S&CO Inc first reported a position in ABBV in Q2 2013 and has held it in 19 quarters since. The position peaked at $15.8M in Q2 2014. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

S&CO Inc held 5,857 shares of AbbVie worth $1.27M as of Q1 2026.
S&CO Inc sold 235 AbbVie shares in Q1 2026, an estimated $52.1K.
AbbVie made up 0.08% of S&CO Inc's portfolio in Q1 2026, its #131 holding.
S&CO Inc first reported a position in AbbVie in Q2 2013 and has held it in 19 quarters since.
S&CO Inc's AbbVie position peaked at $15.8M in Q2 2014.
4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on S&CO Inc's 13F filing for Q1 2026, filed 7 May 2026.